Hakan Mellstedt

Tumor immunology with a focus on immunotherapy using monoclonal antibodies and cancer vaccines. The present research is addressing structural and functional characterization of ROR1 in hematological malignancies and solid tumors and the developement of therapeutic strategies using small molecules targeting the TK domain of ROR1 as well as monoclonal antibodies recognizing the extracellular part of ROR1. A future strategy will also include developement of active ROR1 specific immunotherapy